Trazimera, a Biosimilar to Herceptin, Gets FDA Approval
The Food and Drug Administration (FDA) has approved Trazimera (trastuzumab-qyyp; Pfizer), a biosimilar to Herceptin (trastuzumab; Genentech).
Breast Cancer News
BREAST CANCER ADVISOR
Breast Cancer News
First Cancer Immunotherapy Regimen Approved for Breast Cancer Treatment
The Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq (atezolizumab; Genentech) in combination with Abraxane.
Fixed-Dose Trastuzumab in Early-Stage HER2-Positive Breast Cancer: Unanswered Questions
A study of patients with HER2-positive early-stage breast cancer receiving fixed doses of trastuzumab found that 67% and 38% of patients were underdosed in the loading and maintenance settings, respectively.
Herceptin Hylecta Approved for the Treatment of HER2-Overexpressing Breast Cancer
The Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for the treatment of HER2-overexpressing breast cancer.
American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
Testing should be made available to all patients with a family or personal history of breast cancer, according to the American Society of Breast Surgeons.
Birinapant Found to Enhance Antitumor Activity of CAR-T in Solid Tumor Models
This study provides evidence that birinapant could enhance sensitivity to TNF, effectively boosting the activity of CAR-T therapy in solid tumors.
Biosimilar Cancer Treatment Ontruzant Gets FDA Approval
Prior to treatment, HER2 testing using FDA-approved tests should be performed.
Effect of Chemotherapy on Prometastatic Extracellular Vesicles Warrants Further Research
Breast cancer models showed certain neoadjuvant chemotherapy promoted prometastatic behavior.
Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications
Celltrion and Teva announced that the FDA has approved Herzuma (trastuzumab-pkrb) injection, a new biosimilar to Herceptin (trastuzumab; Genentech) for certain HER2-overexpressing breast cancer indications.
Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
Researchers reported that 3 years after whole-breast irradiation and a tumor bed boost, outcomes with hypofractionation and conventional fractionation are similar.
Younger Breast Cancer Patients at Higher Risk for Osteoporosis
Investigators found that incident osteopenia and osteoporosis are significantly higher in young survivors of breast cancer.
Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
CARB-BC predicted grade 3 to 5 adverse events, dose modifications, and hospitalizations.
Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy
Researchers find that surgical decision making is often driven by factors beyond extent of disease.
Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
Among breast cancer patients on adjuvant trastuzumab, lisinopril and carvedilol reduced cardiotoxicity, but only for those in the anthracycline cohort.
Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer
The immune marker PD1 may be prognostic for survival in patients with TNBC who achieve a pathologic complete response after neoadjuvant therapy.
Rates of Adverse Events Similar Regardless of IMRT Boost Type
The rates of adverse events seen across dose schedule type for patients who underwent IMRT were roughly similar.
TAILORx Shows Black Women With Breast Cancer Have Worse Clinical Outcomes
Black women with the most common type of breast cancer had worse clinical outcomes compared with white women, despite receiving similar systemic therapy.
Partial-Breast Irradiation Not Equal to Whole-Breast Irradiation in Early-Stage Breast Cancer
Partial-breast irradiation failed to meet protocol-defined measures for equivalence.
Alpelisib Plus Fulvestrant Continues to Show Improved PFS in PIK3CA-Mutant, HR+, HER2- Advanced Breast Cancer
Alpelisib plus fulvestrant consistently resulted in prolonged PFS among patients with HR-positive, HER2-negative advanced breast cancer who also had PIK3CA mutations.
High CTC Count Favors Chemotherapy in First-Line ER+, HER2- Metastatic Breast Cancer
CTC count may help guide the decision between first-line chemotherapy or endocrine therapy in ER-positive, HER-negative metastatic breast cancer.
Want to read more?
Please login or register first to view this content.
